Minocycline prevents retinal inflammation and vascular permeability following ischemia-reperfusion injury

Journal of Neuroinflammation

Volumn 10, Issue , 2013, Pages

  Abcouwer, Steven F ^a   Lin, Cheng mao ^a   Shanmugam, Sumathi ^a   Muthusamy, Arivalagan ^a   Barber, Alistair J ^b   Antonetti, David A ^a,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Blood retinal barrier; Inflammation; Ischemia reperfusion; Leukostasis; Minocycline; Neurodegeneration; Vascular permeability

Indexed keywords

CASPASE 3; CD11B ANTIGEN; CD4 ANTIGEN; DNA; EVANS BLUE; INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MINOCYCLINE; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; SERPINA3N PROTEIN; TIGHT JUNCTION PROTEIN; TNFRSF12A PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; BONE MARROW CELL; CELL DEATH; CELL DIFFERENTIATION; CELL INVASION; CONTROLLED STUDY; DNA FRAGMENTATION; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVATION; FLOW CYTOMETRY; GENE EXPRESSION; GLIOSIS; IMMUNOREACTIVITY; LEUKOCYTE ADHERENCE; LEUKOCYTE COUNT; LEUKOCYTOSIS; LOADING DRUG DOSE; LYMPHOCYTE; MALE; MICROGLIA; NERVE DEGENERATION; NONHUMAN; RAT; REPERFUSION INJURY; RETINA CELL; RETINITIS;

ANIMALS; BLOOD-RETINAL BARRIER; CAPILLARY PERMEABILITY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; INFLAMMATION; MALE; MINOCYCLINE; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; REPERFUSION INJURY; RETINA;

EID: 84889842716     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-10-149     Document Type: Article

References (70)

1. Osborne NN, Casson RJ, Wood JP, Chidlow G, Graham M, Melena J. Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Prog Retin Eye Res 2004, 23:91-147. 10.1016/j.preteyeres.2003.12.001, 14766318.
2. Jehle T, Wingert K, Dimitriu C, Meschede W, Lasseck J, Bach M, Lagreze WA. Quantification of ischemic damage in the rat retina: a comparative study using evoked potentials, electroretinography, and histology. Invest Ophthalmol Vis Sci 2008, 49:1056-1064. 10.1167/iovs.07-1050, 18326730.
3. Husain S, Potter DE, Crosson CE. Opioid receptor-activation: retina protected from ischemic injury. Invest Ophthalmol Vis Sci 2009, 50:3853-3859. 10.1167/iovs.08-2907, 19324855.
4. Konno T, Sato A, Uchibori T, Nagai A, Kogi K, Nakahata N. Adenosine A2A receptor mediated protective effect of 2-(6-cyano-1-hexyn-1-yl)adenosine on retinal ischaemia/reperfusion damage in rats. Br J Ophthalmol 2006, 90:900-905. 10.1136/bjo.2006.091496, 1857139, 16613921.
5. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007, 171:53-67. 10.2353/ajpath.2007.061237, 1941589, 17591953.
6. Kim BJ, Braun TA, Wordinger RJ, Clark AF. Progressive morphological changes and impaired retinal function associated with temporal regulation of gene expression after retinal ischemia/reperfusion injury in mice. Mol Neurodegener 2013, 8:21. 10.1186/1750-1326-8-21, 3695831, 23800383.
7. Abcouwer SF, Lin CM, Wolpert EB, Shanmugam S, Schaefer EW, Freeman WM, Barber AJ, Antonetti DA. Effects of ischemic preconditioning and bevacizumab on apoptosis and vascular permeability following retinal ischemia-reperfusion injury. Invest Ophthalmol Vis Sci 2010, 51:5920-5933. 10.1167/iovs.10-5264, 20554620.
8. Danesh-Meyer HV, Kerr NM, Zhang J, Eady EK, O'Carroll SJ, Nicholson LF, Johnson CS, Green CR. Connexin43 mimetic peptide reduces vascular leak and retinal ganglion cell death following retinal ischaemia. Brain 2012, 135:506-520. 10.1093/brain/awr338, 22345088.
9. Zheng L, Gong B, Hatala DA, Kern TS. Retinal ischemia and reperfusion causes capillary degeneration: similarities to diabetes. Invest Ophthalmol Vis Sci 2007, 48:361-367. 10.1167/iovs.06-0510, 17197555.
10. Chen B, Caballero S, Seo S, Grant MB, Lewin AS. Delivery of antioxidant enzyme genes to protect against ischemia/reperfusion-induced injury to retinal microvasculature. Invest Ophthalmol Vis Sci 2009, 50:5587-5595. 10.1167/iovs.09-3633, 3756491, 19628743.
11. Wei Y, Gong J, Yoshida T, Eberhart CG, Xu Z, Kombairaju P, Sporn MB, Handa JT, Duh EJ. Nrf2 has a protective role against neuronal and capillary degeneration in retinal ischemia-reperfusion injury. Free Radic Biol Med 2011, 51:216-224. 10.1016/j.freeradbiomed.2011.04.026, 21545836.
12. Gustavsson C, Agardh CD, Hagert P, Agardh E. Inflammatory markers in nondiabetic and diabetic rat retinas exposed to ischemia followed by reperfusion. Retina 2008, 28:645-652. 10.1097/IAE.0b013e31815ec32d, 18398369.
13. Chen FT, Yang CM, Yang CH. The protective effects of the proteasome inhibitor bortezomib (velcade) on ischemia-reperfusion injury in the rat retina. PLoS One 2013, 8:e64262. 10.1371/journal.pone.0064262, 3653862, 23691186.
14. Dvoriantchikova G, Barakat D, Brambilla R, Agudelo C, Hernandez E, Bethea JR, Shestopalov VI, Ivanov D. Inactivation of astroglial NF-kappaB promotes survival of retinal neurons following ischemic injury. Eur J Neurosci 2009, 30:175-185. 10.1111/j.1460-9568.2009.06814.x, 2778328, 19614983.
15. Dvoriantchikova G, Barakat DJ, Hernandez E, Shestopalov VI, Ivanov D. Liposome-delivered ATP effectively protects the retina against ischemia-reperfusion injury. Mol Vis 2010, 16:2882-2890. 3013064, 21203410.
16. Dvoriantchikova G, Barakat DJ, Hernandez E, Shestopalov VI, Ivanov D. Toll-like receptor 4 contributes to retinal ischemia/reperfusion injury. Mol Vis 2010, 16:1907-1912. 2956702, 21031135.
17. Hangai M, Yoshimura N, Honda Y. Increased cytokine gene expression in rat retina following transient ischemia. Ophthalmic Res 1996, 28:248-254. 10.1159/000267910, 8878188.
18. Nishijima K, Kiryu J, Tsujikawa A, Honjo M, Nonaka A, Yamashiro K, Kamizuru H, Ieki Y, Tanihara H, Honda Y, Ogura Y. Inhibitory effects of antithrombin III on interactions between blood cells and endothelial cells during retinal ischemia-reperfusion injury. Invest Ophthalmol Vis Sci 2003, 44:332-341. 10.1167/iovs.02-0493, 12506093.
19. Hirose F, Kiryu J, Miyamoto K, Nishijima K, Miyahara S, Katsuta H, Tamura H, Honda Y. In vivo evaluation of retinal injury after transient ischemia in hypertensive rats. Hypertension 2004, 43:1098-1102. 10.1161/01.HYP.0000123069.02156.8a, 15007035.
20. Miyahara S, Kiryu J, Tsujikawa A, Katsuta H, Nishijima K, Miyamoto K, Yamashiro K, Nonaka A, Honda Y. Argatroban attenuates leukocyte- and platelet-endothelial cell interactions after transient retinal ischemia. Stroke 2003, 34:2043-2049. 10.1161/01.STR.0000083052.01361.3D, 12869718.
21. Cho KJ, Kim JH, Park HY, Park CK. Glial cell response and iNOS expression in the optic nerve head and retina of the rat following acute high IOP ischemia-reperfusion. Brain Res 2011, 1403:67-77.
22. Hirata A, Inatani M, Inomata Y, Yonemura N, Kawaji T, Honjo M, Tanihara H. Y-27632, a Rho-associated protein kinase inhibitor, attenuates neuronal cell death after transient retinal ischemia. Graefes Arch Clin Exp Ophthalmol 2008, 246:51-59.
23. Griffin MO, Ceballos G, Villarreal FJ. Tetracycline compounds with non-antimicrobial organ protective properties: possible mechanisms of action. Pharmacol Res 2011, 63:102-107. 10.1016/j.phrs.2010.10.004, 3031662, 20951211.
24. Plane JM, Shen Y, Pleasure DE, Deng W. Prospects for minocycline neuroprotection. Arch Neurol 2010, 67:1442-1448. 3127230, 20697034.
25. Krady JK, Basu A, Allen CM, Xu Y, LaNoue KF, Gardner TW, Levison SW. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes 2005, 54:1559-1565. 10.2337/diabetes.54.5.1559, 15855346.
26. Chang CJ, Cherng CH, Liou WS, Liao CL. Minocycline partially inhibits caspase-3 activation and photoreceptor degeneration after photic injury. Ophthalmic Res 2005, 37:202-213. 10.1159/000086610, 15990464.
27. Zhang C, Lei B, Lam TT, Yang F, Sinha D, Tso MO. Neuroprotection of photoreceptors by minocycline in light-induced retinal degeneration. Invest Ophthalmol Vis Sci 2004, 45:2753-2759. 10.1167/iovs.03-1344, 15277501.
28. Levkovitch-Verbin H, Kalev-Landoy M, Habot-Wilner Z, Melamed S. Minocycline delays death of retinal ganglion cells in experimental glaucoma and after optic nerve transection. Arch Ophthalmol 2006, 124:520-526. 10.1001/archopht.124.4.520, 16606878.
29. Bosco A, Inman DM, Steele MR, Wu G, Soto I, Marsh-Armstrong N, Hubbard WC, Calkins DJ, Horner PJ, Vetter ML. Reduced retina microglial activation and improved optic nerve integrity with minocycline treatment in the DBA/2 J mouse model of glaucoma. Invest Ophthalmol Vis Sci 2008, 49:1437-1446. 10.1167/iovs.07-1337, 18385061.
30. Baptiste DC, Powell KJ, Jollimore CA, Hamilton C, LeVatte TL, Archibald ML, Chauhan BC, Robertson GS, Kelly ME. Effects of minocycline and tetracycline on retinal ganglion cell survival after axotomy. Neuroscience 2005, 134:575-582. 10.1016/j.neuroscience.2005.04.011, 15939545.
31. Yang L, Kim JH, Kovacs KD, Arroyo JG, Chen DF. Minocycline inhibition of photoreceptor degeneration. Arch Ophthalmol 2009, 127:1475-1480. 10.1001/archophthalmol.2009.288, 19901213.
32. Chen Y-I, Lee Y-J, Wilkie DA, Lin C-T. Evaluation of potential topical and systemic neuroprotective agents for ocular hypertension-induced retinal ischemia-reperfusion injury. Vet Ophthalmol 2013, doi: 10.1111/vop.12105.
33. Xu Q, Qaum T, Adamis AP. Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest Ophthalmol Vis Sci 2001, 42:789-794.
34. Fanning AS, Anderson JM. Zonula occludens-1 and -2 are cytosolic scaffolds that regulate the assembly of cellular junctions. Ann N Y Acad Sci 2009, 1165:113-120. 10.1111/j.1749-6632.2009.04440.x, 3759978, 19538295.
35. Laitinen L. Griffonia simplicifolia lectins bind specifically to endothelial cells and some epithelial cells in mouse tissues. Histochem J 1987, 19:225-234. 10.1007/BF01680633, 3597137.
36. Matsumoto H, Kumon Y, Watanabe H, Ohnishi T, Shudou M, Ii C, Takahashi H, Imai Y, Tanaka J. Antibodies to CD11b, CD68, and lectin label neutrophils rather than microglia in traumatic and ischemic brain lesions. J Neurosci Res 2007, 85:994-1009. 10.1002/jnr.21198, 17265469.
37. Chen YD, Xu X, Xia X, Wu H, Liu K, Zheng Z, Zhu D. MMP9 is involved in glycation end-products induced increase of retinal vascular permeability in rats and the therapeutic effect of minocycline. Curr Eye Res 2008, 33:977-983. 10.1080/02713680802450984, 19085380.
38. Sun C, Li XX, He XJ, Zhang Q, Tao Y. Neuroprotective effect of minocycline in a rat model of branch retinal vein occlusion. Exp Eye Res 2013, 113C:105-116.
39. Nagel S, Su Y, Horstmann S, Heiland S, Gardner H, Koziol J, Martinez-Torres FJ, Wagner S. Minocycline and hypothermia for reperfusion injury after focal cerebral ischemia in the rat: effects on BBB breakdown and MMP expression in the acute and subacute phase. Brain Res 2008, 1188:198-206.
40. Sutton TA, Kelly KJ, Mang HE, Plotkin Z, Sandoval RM, Dagher PC. Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury. Am J Physiol Renal Physiol 2005, 288:F91-F97.
41. Wasserman JK, Schlichter LC. Minocycline protects the blood-brain barrier and reduces edema following intracerebral hemorrhage in the rat. Exp Neurol 2007, 207:227-237. 10.1016/j.expneurol.2007.06.025, 17698063.
42. Koistinaho M, Malm TM, Kettunen MI, Goldsteins G, Starckx S, Kauppinen RA, Opdenakker G, Koistinaho J. Minocycline protects against permanent cerebral ischemia in wild type but not in matrix metalloprotease-9-deficient mice. J Cereb Blood Flow Metab 2005, 25:460-467. 10.1038/sj.jcbfm.9600040, 15674236.
43. Wu J, Yang S, Hua Y, Liu W, Keep RF, Xi G. Minocycline attenuates brain edema, brain atrophy and neurological deficits after intracerebral hemorrhage. Acta Neurochir Suppl 2010, 106:147-150. 10.1007/978-3-211-98811-4_26, 19812938.
44. Wu J, Yang S, Xi G, Fu G, Keep RF, Hua Y. Minocycline reduces intracerebral hemorrhage-induced brain injury. Neurol Res 2009, 31:183-188. 10.1179/174313209X385680, 2659336, 19061541.
45. Homsi S, Federico F, Croci N, Palmier B, Plotkine M, Marchand-Leroux C, Jafarian-Tehrani M. Minocycline effects on cerebral edema: relations with inflammatory and oxidative stress markers following traumatic brain injury in mice. Brain Res 2009, 1291:122-132.
46. Mishra MK, Dutta K, Saheb SK, Basu A. Understanding the molecular mechanism of blood-brain barrier damage in an experimental model of Japanese encephalitis: correlation with minocycline administration as a therapeutic agent. Neurochem Int 2009, 55:717-723. 10.1016/j.neuint.2009.07.006, 19628016.
47. Ryu JK, McLarnon JG. Minocycline or iNOS inhibition block 3-nitrotyrosine increases and blood-brain barrier leakiness in amyloid beta-peptide-injected rat hippocampus. Exp Neurol 2006, 198:552-557. 10.1016/j.expneurol.2005.12.016, 16480717.
48. Zhao C, Ling Z, Newman MB, Bhatia A, Carvey PM. TNF-alpha knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice. Neurobiol Dis 2007, 26:36-46. 10.1016/j.nbd.2006.11.012, 1892817, 17234424.
49. Cukras CA, Petrou P, Chew EY, Meyerle CB, Wong WT. Oral minocycline for the treatment of diabetic macular edema (DME): results of a phase I/II clinical study. Invest Ophthalmol Vis Sci 2012, 53:3865-3874. 10.1167/iovs.11-9413, 3390218, 22589436.
50. Kim HS, Suh YH. Minocycline and neurodegenerative diseases. Behav Brain Res 2009, 196:168-179. 10.1016/j.bbr.2008.09.040, 18977395.
51. Baptiste DC, Hartwick AT, Jollimore CA, Baldridge WH, Seigel GM, Kelly ME. An investigation of the neuroprotective effects of tetracycline derivatives in experimental models of retinal cell death. Mol Pharmacol 2004, 66:1113-1122. 10.1124/mol.104.001081, 15304547.
52. Mathalone N, Lahat N, Rahat MA, Bahar-Shany K, Oron Y, Geyer O. The involvement of matrix metalloproteinases 2 and 9 in rat retinal ischemia. Graefes Arch Clin Exp Ophthalmol 2007, 245:725-732. 10.1007/s00417-006-0362-y, 17024442.
53. Krueger M, Hartig W, Reichenbach A, Bechmann I, Michalski D. Blood-brain barrier breakdown after embolic stroke in rats occurs without ultrastructural evidence for disrupting tight junctions. PLoS One 2013, 8:e56419. 10.1371/journal.pone.0056419, 3582567, 23468865.
54. Graeber MB, Li W, Rodriguez ML. Role of microglia in CNS inflammation. FEBS Lett 2011, 585:3798-3805. 10.1016/j.febslet.2011.08.033, 21889505.
55. Nishiwaki A, Ueda T, Ugawa S, Shimada S, Ogura Y. Upregulation of P-selectin and intercellular adhesion molecule-1 after retinal ischemia-reperfusion injury. Invest Ophthalmol Vis Sci 2003, 44:4931-4935. 10.1167/iovs.02-1324, 14578419.
56. Tsujikawa A, Ogura Y, Hiroshiba N, Miyamoto K, Kiryu J, Tojo SJ, Miyasaka M, Honda Y. Retinal ischemia-reperfusion injury attenuated by blocking of adhesion molecules of vascular endothelium. Invest Ophthalmol Vis Sci 1999, 40:1183-1190.
57. Gregerson DS, Yang J. CD45-positive cells of the retina and their responsiveness to in vivo and in vitro treatment with IFN-gamma or anti-CD40. Invest Ophthalmol Vis Sci 2003, 44:3083-3093. 10.1167/iovs.02-1014, 12824255.
58. Sedgwick JD, Schwender S, Imrich H, Dorries R, Butcher GW, ter Meulen V. Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. Proc Natl Acad Sci USA 1991, 88:7438-7442. 10.1073/pnas.88.16.7438, 52311, 1651506.
59. Sedgwick JD, Schwender S, Gregersen R, Dorries R, ter Meulen V. Resident macrophages (ramified microglia) of the adult brown Norway rat central nervous system are constitutively major histocompatibility complex class II positive. J Exp Med 1993, 177:1145-1152. 10.1084/jem.177.4.1145, 2190968, 8459208.
60. Renno T, Krakowski M, Piccirillo C, Lin JY, Owens T. TNF-alpha expression by resident microglia and infiltrating leukocytes in the central nervous system of mice with experimental allergic encephalomyelitis. Regulation by Th1 cytokines. J Immunol 1995, 154:944-953.
61. Dick AD, Ford AL, Forrester JV, Sedgwick JD. Flow cytometric identification of a minority population of MHC class II positive cells in the normal rat retina distinct from CD45lowCD11b/c + CD4low parenchymal microglia. Br J Ophthalmol 1995, 79:834-840. 10.1136/bjo.79.9.834, 505270, 7488603.
62. Lehmann U, Heuss ND, McPherson SW, Roehrich H, Gregerson DS. Dendritic cells are early responders to retinal injury. Neurobiol Dis 2010, 40:177-184. 10.1016/j.nbd.2010.05.022, 2926161, 20580926.
63. Holling TM, Schooten E, van Den Elsen PJ. Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men. Hum Immunol 2004, 65:282-290. 10.1016/j.humimm.2004.01.005, 15120183.
64. Nikodemova M, Watters JJ, Jackson SJ, Yang SK, Duncan ID. Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII. J Biol Chem 2007, 282:15208-15216. 10.1074/jbc.M611907200, 17395590.
65. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 1998, 95:15769-15774. 10.1073/pnas.95.26.15769, 28119, 9861045.
66. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000, 6:797-801. 10.1038/77528, 10888929.
67. Vincent JA, Mohr S. Inhibition of caspase-1/interleukin-1beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes 2007, 56:224-230. 10.2337/db06-0427, 17192486.
68. Seo JH, Guo S, Lok J, Navaratna D, Whalen MJ, Kim KW, Lo EH. Neurovascular matrix metalloproteinases and the blood-brain barrier. Curr Pharm Des 2012, 18:3645-3648. 10.2174/138161212802002742, 3814178, 22574977.
69. Griffin MO, Fricovsky E, Ceballos G, Villarreal F. Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol 2010, 299:C539-C548. 10.1152/ajpcell.00047.2010, 2944325, 20592239.
70. Seal JB, Gewertz BL. Vascular dysfunction in ischemia-reperfusion injury. Ann Vasc Surg 2005, 19:572-584. 10.1007/s10016-005-4616-7, 15981128.